TABLE 1.
Unweighted Baseline Patient Demographics and Clinical Characteristics
| Characteristic | Venetoclax Cohort (n = 99) | BTKi Cohort (n = 181) |
|---|---|---|
| Age at 2L initiation, years, median (IQR) | 74.0 (66-80) | 76.0 (68-81) |
| Sex,a No. (%) | ||
| Female | 31 (31.3) | 63 (34.8) |
| Male | 68 (68.7) | 118 (65.2) |
| Race,a No. (%) | ||
| Asian | 0 (0.0) | 1 (0.6) |
| Black | 10 (10.1) | 15 (8.3) |
| Hispanic | 5 (5.1) | 12 (6.6) |
| White | 84 (84.8) | 153 (84.5) |
| Geographical region, No. (%) | ||
| South | 35 (35.4) | 74 (40.9) |
| Midwest | 32 (32.3) | 43 (23.8) |
| West | 25 (25.3) | 48 (26.5) |
| Northeast | 7 (7.1) | 16 (8.8) |
| Type of insurance, No. (%) | ||
| Commercial | 23 (23.2) | 45 (24.9) |
| Medicare | 76 (76.8) | 136 (75.1) |
| Comorbidities, No. (%) | ||
| Myocardial infarction | 9 (9.1) | 10 (5.5) |
| Congestive heart failure | 20 (20.2) | 27 (14.9) |
| Diabetes | 22 (22.2) | 48 (26.5) |
| Renal disease | 27 (27.3) | 56 (30.9) |
| Hypertension | 72 (72.7) | 121 (66.9) |
| Atrial fibrillation | 29 (29.3)** | 24 (13.3) |
| Acute kidney failure | 22 (22.2) | 29 (16.0) |
| CCI score, median (IQR) | 3.0 (2-4) | 3.0 (2-4) |
| First line of therapy, No. (%) | ||
| BTKi-based regimen | 59 (59.6)*** | 0 (0.0) |
| CT/CIT regimen | 24 (24.2) | 112 (61.9) |
| IT monotherapy | 16 (16.2) | 64 (35.4) |
| Venetoclax-based regimen | 0 (0.0) | 5 (2.8) |
| Year of 2L initiation, No. (%) | ||
| 2018 | 12 (12.1) | 32 (17.7) |
| 2019 | 26 (26.3) | 53 (29.3) |
| 2020 | 35 (35.4) | 55 (30.4) |
| 2021 | 26 (26.3) | 41 (22.7) |
| Time to 2L, months, median (IQR) | 42.9 (26.3-71.5) | 46.7 (24.4-69.4) |
| All-cause medication cost PPPM, USD, mean (SD) | $4,828 ($5,295)*** | $2,200 ($3,224) |
Abbreviations: 2L, second-line; BTKi, Bruton tyrosine kinase inhibitor; CCI, Charleston Comorbidity Index; CT/CIT, chemotherapy/chemoimmunotherapy; IQR, interquartile range; IT, immunotherapy; PPPM, per patient per month; SD, standard deviation; USD, US dollars.
a
As determined by insurance plan.
**P < .001.
***P < .0001.